# Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

> **NCT00079937** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 628 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo
- **DRUG:** Fluticasone

## Key facts

- **NCT ID:** NCT00079937
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079937, "Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00079937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*